Development of second-generation heat shock protein 90 inhibitors has progressed to the point that the first pivotal phase III trials of these novel agents in several types of cancer are getting underway. But the best is yet to come, Dr. David B. Solit predicted at the annual meeting of the American Thyroid Association. Although the clinical trials experience to date with the second-generation heat shock protein 90 (Hsp90) inhibitors suggests they may provide an important new approach to cancer therapy,...